Anti-Kairi Virus (KRIV) Nucleocapsid antibody
Recognises the viral capsid protein which encloses the nucleocapsids of Kairi Virus (KRIV)
Western blot analysis of BHK-21 cells infected with the Kairi virus
|Antibody||Anti-Kairi Virus (KRIV) Nucleocapsid antibody|
|Antigen Peptide||KLH conjugated synthetic peptide crb1200004e|
|Protein ID||UniProtKB - B8R6C1|
|Target Protein Species||Kairi Virus|
|Target||Kairi Virus Nucleocapsid|
|Storage Stabilisers||This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/ thaw cycles.|
|Storage||This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/ thaw cycles.|
Dunlop et al., (2018). Development of reverse genetics systems and investigation of host response antagonism and reassortment potential for Cache Valley and Kairi viruses, two emerging orthobunyaviruses of the Americas. PLoS Negl Trop Dis. 12(10):e0006884. doi: 10.1371/journal.pntd.0006884. PMID: 30372452.
KRIV belongs to the Peribunyaviridae family of viruses (previously called Bunyaviridae). KRIV was first isolated from mosquito species in Trinidad including Aedes, Wyeomia, Culex and Psorophora spp. and has since been isolated from mosquitoes and vertebrates in Central and South America. Although between 6–18% of humans and up to 48% of horses have antibodies to KRIV, it does not cause any documented clinical disease symptoms in humans or animals. KRVI consists of three genome segments (called L [large], M [medium] and S [small]) which are encapsidated by the nucleocapsid (N) protein. These segments associate with the viral RNA-dependent RNA polymerase, the L protein, to form ribonucleoprotein complexes (RNP) termed nucleocapsids. RNPs are contained within a lipid envelope also containing the viral glycoproteins, Gn and Gc.